Market Statistics for OMT in Coma and Brainstem Death Diagnosis

The Comatose Monitoring and Brainstem Death market can be defined as that segment of the medical care market devoted to the care and management of comatose head injury patients (240,000) as well as patients in coma due to sub-arachnoid hemorrhages and other non-head-injuries (340,000).  A subset of this population (55,000) will die while in the ICU, many (30,000) requiring official diagnosis of brain death.  The average head injury coma patient spends seven days in the NICU while a portion of these patients spend an average of 25 days in prolonged state of coma at an estimated cost of between US$20,000-40,000 per diem.  Non-head-injury coma patients can be expected to remain in that state for 4 days on average.

In total, hospitals worldwide incur over 2.5 million comatose patient days annually at a cost in excess of US$40 billion.  These figures translate into an annual market for OMT monitoring in the NICU of over US$671 million and an economic benefit to society due to improved care of an estimated 15%, or US$6.0 billion. 

EyeTect anticipates the following conservative market penetration and growth rates following commercial launch of the TMU in 2010:

Coma & BSD Market	2010	2011	2012	2013	2014
--Market Penetration	1.5%	3.5%	7.0%	12.0%	20.0%
--Market Growth	3.0%	3.0%	3.0%	3.0%	3.0%

This OMT market application is a ‘white market’, and its stakeholders stand to gain substantially in terms of improved patient care and economics.  EyeTect, LLC’s TMU will be the only product available for continuous, non-invasive of monitoring of brainstem activity.  The product is straight-forward and easy to use.